Last week, people from both sides of the Pacific, all of them with an interest in China life science, came together for ChinaBio Day, which was held in San Francisco in conjunction with BioPharma America. Experts with partnership experience brought their expertise to the Panel Discussions, which we covered in detail. The panel subjects were: A Big Pharma Perspective on Leveraging China’s Resources (see story), the Impact of the Financial Crisis on China Partnering (see story), Case Studies of Successful Partnerships (see story), and Factors for Success in China Partnerships (see story).
Genzyme Corp. (NSDQ: GENZ), the third largest biotech company by revenue, began construction of a $100 million R&D center in Beijing (see story). The center, which will eventually employ 350 people, will comprise 200,000 square feet (18,580 square meters) and is expected to be completed in 2011. It will seek to discover and develop novel biologics and other gene therapies. Genzyme says it is interested in China because of the talent and the market.
Read the rest at Seeking Alpha
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment